Anti-CD152 Antibody – Pipeline Insights – 2018

SKU: DPI49 | Last Updated On: 2019-04-09 | No. of Pages: 175 | Available Formats

Anti-CD152 Antibody – Pipeline Insights

  • The “Anti-CD152 Antibody – Pipeline Insights, 2018″ report covers an in-depth analysis of Anti-CD152 Antibody drug molecules currently undergoing clinical studies.
  • It provides a deep understanding of potential Anti-CD152 Antibody drug molecules across all drug development phases.
  • The report assesses the pipeline Anti-CD152 Antibody molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products), molecule type (small molecules, Biologics and others), drug target, mechanism of action (MoA), and route of administration (oral, IV, and others). The report provides a snapshot of discontinued and dormant drugs too.
  • In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
  • The report covers company profiles key players in developing Anti-CD152 Antibody drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.

 

The scope of the report

• Provides comprehensive understanding of active Anti-CD152 Antibody pipeline drug candidates

• Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.

• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration

• Provides a comparative analysis of key marketed products and pipeline drug candidates

• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators

• Provides key info on players involved in clinical R&D of Anti-CD152 Antibody drug candidates.

• Provides in-depth coverage of key news related to Anti-CD152 Antibody drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.

 

Reasons To Buy

• To obtain an understanding of the current Anti-CD152 Antibody pipeline landscape.

• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.

• To valuably optimize R&D activities in-line with robust therapeutic drug markets.

• To devise strategic initiatives by identifying prospective partners with progressing projects.

Anti-CD152 Antibody

  • Alternative names of anti-CD152 include Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CTLA4. CD152 is a 33 kD member of the immunoglobulin superfamily. It is a cell surface glycoprotein expressed on activated T and B-lymphocytes.
  • CD152 is same as CD28 in amino acid sequence, genomic organization, and structure and they share common B7 family counter-receptors (B7-1, B7-2). CD28 delivers a costimulatory signal in T cell activation, and CTLA-4 negatively regulates cell-mediated immune responses.
  • CD152 plays a role in the induction and maintenance of immunological tolerance, as well as the development of protective immunity and thymocyte regulation. CTLA-4 is a group of inhibitory receptors that are being explored as cancer treatment targets through immune checkpoint blockade.
  • Anti-CTLA4 (CD152) Antibody, clone 9H10 used in Western Blotting, Flow Cytometry, Immunoprecipitation that acts by enhancing T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions.
  • The mouse monoclonal Anti-CD152, clone BNI3, may be used for flow cytometric analysis of intracellular or surface CTLA-4 expression and is used for neutralization of CTLA-4 when expressed at the cell surface, thus used for the detection of CD152. AGEN1884, AGEN1181 are the anti-CTLA4 inhibitors by Agenus Inc, used in treating various types of cancer.
  • Recently, CStone Pharmaceuticals announced its IND application for CS1002, an investigational CTLA-4 monoclonal antibody in 2018. Ipilimumab, an anti-CTLA4 antibody was approved by the U.S. FDA for the treatment of melanoma, a type of skin cancer.
  • Its Clinical development was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. ImmunOs Therapeutics AG is exploring novel family classes of therapeutics to stimulate the immune system and to increase the efficacy of checkpoint inhibitors (such as CTLA-4) and co-stimulatory agonists in multiple cancers (Pancreatic, Colon, Melanoma, Lymphoma, and Breast).
  • The agreement of CBT pharmaceuticals gives exclusive worldwide development and commercialization rights to a novel, recombinant, human monoclonal antibody of Crown Bioscience, which targets a differentiated epitope on the CTLA-4 molecule.
  • FPT155 (CD80-Fc), by five prime therapeutics, being studied for the treatment of solid tumors uses the binding interactions of soluble CD80 to: Directly engage CD28 to enhance its co-stimulatory activity, block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation. ONC-392, a novel Anti CTLA 4 monoclonal antibody developed by OncoImmune Inc, for treating cancer is in the preclinical stage of drug development and recently announced that it has entered into an exclusive option and license agreement with Pfizer. Tremelimumab (CP-675206), by Pfizer, is used for treating Head and neck cancer; Liver cancer, etc. are in phase III trials of Drug Development.
  • Xencor Inc, milestones for tumor microenvironment-targeting bispecific antibodies include Initiating Phase 1 trial to evaluate XmAb®20717, a PD-1 x CTLA-4 dual checkpoint inhibitor, Files IND for XmAb22841, a CTLA-4 x LAG-3 dual checkpoint inhibitor for the treatment of multiple oncology indications in 2018.
  • The factors driving the global anti-CD152 antibody therapeutics market are high incidence rates of various types of cancers, the rise in investment in health care by the government and private organizations, increase in demand for minimally invasive surgeries, growing awareness about health, and early diagnosis of diseases.
  • However, the rise in the cost of treatment, side effects associated with treatment, and lack of reimbursement policies in developing countries are likely to restrain the market.
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest